Author + information
- Received September 17, 1993
- Revision received December 2, 1994
- Accepted December 8, 1994
- Published online April 1, 1995.
- Stephen G. Ellis, MD, FACCa,*,
- Michael J. Cowley, MD, FACC*,
- Patrick L. Whitlow, MD, FACCa,
- Michel Vandormael, MD, FACC†,
- A. Michael Lincoff, MD, FACCa,
- Germano DiSciascio, MD, FACC*,
- Larry S. Dean, MD, FACC‡,
- Eric J. Topol, MD, FACCa,
- for the Multivessel Angioplasty Prognosis Study (MAPS) Group
- ↵*Address for correspondence: Dr. Stephen G. Ellis, The Cleveland Clinic Foundation, Department of Cardiology, 9500 Euclid Avenue, F25, Cleveland, Ohio 44195-5066.
Objectives. This study sought to ascertain whether early and 12-month clinical outcomes after percutaneous coronary revascularization have improved between 1986–1987 and 1991.
Background. Since the mid-1980s, when the results of percutaneous revascularization were considered to be somewhat static, justifying large-scale clinical trials of percutaneous transluminal coronary angioplasty versus other modes of therapy, balloon technology has improved, and several new percutaneous revascularization techniques have become available. The clinical results of the current integrated approach to revascularization compared with those for coronary angioplasty alone in the late 1980s are not known.
Methods. In this prospective case-control study, 200 consecutively treated patients with multivessel disease in 1991 were studied prospectively and compared with 400 consecutive patients from the same centers during 1986–1987. Patients from 1991 were matched with earlier patients on the basis of four previously described prognostic determinants (left ventricular ejection fraction, presence of unstable angina, diabetes and target lesion morphology score) and the treating institution and were assessed for treatment outcome (completeness of revascularization, procedural success and event-free survival [freedom from death, myocardial infarction and further revascularization]).
Results. The 1991 cohort of patients was older (mean [±SD] age 62 ± 11 vs. 58 ± 11 years, p < 0.001) and tended to have slightly worse left ventricular function (ejection fraction 56 ± 10% vs. 58 ± 11%, p = 0.009) than the 1986–1987 cohort. Overall lesion morphology risk scores were similar. New devices (other than coronary angioplasty) were used in 26% of patients. The 1991 patient cohort had more frequent total revascularization (35% vs. 21%, p = 0.003), fewer emergency bypass operations (1.0% vs. 5.5%, p = 0.006) and an improved overall procedural success rate (90% vs. 84%, p = 0.04). In addition, at 12 months the event-free survival rate was superior in the 1991 cohort (73.3% vs. 63.6%, p = 0.02), although there was no difference in infarct-free survival rate (94.6% vs. 93.2%, p = NS).
Conclusions. Improved results with percutaneous revascularization in 1991 have important implications for patient care and interpretation of ongoing randomized trials enrolling patients in the late 1980s and intending to compare standard coronary angioplasty with other forms of therapy.
This study was supported in part by Grant HL-38529-03 from the National Heart. Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland and a grant from Medtronic Inc., Minneapolis, Minnesota. A complete list of the coinvestigators appears in the Appendix.
- Received September 17, 1993.
- Revision received December 2, 1994.
- Accepted December 8, 1994.
- North American Society of Pacing and Electrophysiology; American College of Cardiology; American Heart Association, Inc.; and European Society of Cardiology.